TMC649128 + pegylated interferon + ribavirin

**TMC649128 + pegylated interferon + ribavirin** is a combination therapy investigated for the treatment of chronic hepatitis C virus (HCV) infection. TMC649128 is a nucleoside inhibitor (NI) of the HCV NS5B polymerase that exhibits antiviral activity across multiple HCV genotypes and has a high genetic barrier to resistance. Pegylated interferon (typically alpha-2a or alpha-2b) is a biologic agent that stimulates host immune responses to viral infections, while ribavirin is a small molecule nucleoside analog with broad-spectrum antiviral activity that enhances the efficacy of interferon-based regimens. In clinical trials, this triple combination aimed to enhance antiviral efficacy as compared to standard dual treatment, particularly for difficult-to-treat or genotype 1 HCV. TMC649128 was in investigative stages paired with pegylated interferon and ribavirin regimens, which, before direct-acting antivirals, were the standard of care for hepatitis C[2][5][7][9][10][1][6].